“…An aberrant increase in the levels of β-catenin exerts oncogenic effects via the activation of downstream gene expression programs in colorectal cancer (Morin et al, 1997;Rahmani, Avan, Hashemy, & Hassanian, 2018;Vermeulen et al, 2010), endometrial cancer (Giannakis et al, 2014;Liu, Chang, Lu, & Xiang, 2019), breast cancer (Gao et al, 2019;Khramtsov et al, 2010;Mohammadi-Yeganeh, Hosseini, & Paryan, 2019;Rahmani et al, 2019), prostate cancer (Pashirzad et al, 2019), bladder cancer (Xie et al, 2019), lung cancer (Wang, Zhou, Xu, & Hu, 2018b), glioblastoma (He et al, 2019) as well as in blood malignancies (Staal & Sen, 2008;Zhao et al, 2007). More specifically, ≥85% of pediatric T-ALL patients display increased β-catenin expression and upregulation of the Wnt target genes AXIN2, C-MYC, TCFL, and LEF (Arensman et al, 2014;Fernandes et al, 2017;Ng et al, 2014). Furthermore, about 30% of adult T-ALL patients displayed high expression of lymphoid enhancer-binding Factor 1 (LEF1) messenger RNA (mRNA; Guo et al, 2015).…”